Pluri Takes 50% Stake in ZEO ScientifiX to Build U.S. Regenerative Medicine Platform
PLUR is trading near its 52-week low of $0.85 (14% above the low) on elevated volume (3.3× avg).
Summary
Pluri signed a definitive strategic agreement with OTCQB-listed ZEO ScientifiX under which Pluri will receive shares equal to 50% of ZEO's outstanding common stock at closing, and ZEO's results will be consolidated into Pluri's financials. ZEO brings a U.S. biologics manufacturing base, an existing product portfolio, a physician network and a sales and marketing organization; Pluri contributes its 3D cell-expansion technology, clinical development experience and its Cellav regenerative aesthetics line, for which ZEO gets exclusive U.S. rights. The deal is expected to close in Q4 2026 and needs ancillary agreements, certain approvals and valuations, but no shareholder vote from either side. For a company of Pluri's size this is a meaningful strategic step toward an actual U.S. commercial channel, though it adds no cash and comes against a going-concern backdrop with less than three months of runway flagged in the September 10-K. Watch for the ancillary agreements and valuations needed to close in Q4 2026.
At the time of this announcement, PLUR was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $0.85 to $4.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.